| Bioactivity | CIGB-300 (P15-Tat) is an anti-casein kinase 2 (CK2) peptide that exhibits anticancer properties by interfering with the phosphorylation of protein kinase CK2. CIGB-300 induces apoptosis in multiple tumor cell lines and can be used in cancer therapy research[1]. |
| CAS | 1072877-99-6 |
| Sequence | Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln-{βAla}-Cys-Trp-Met-Ser-Pro-Arg-His-Leu-Gly-Thr-Cys (Disulfide bridge: Cys15-Cys25) |
| Shortening | GRKKRRQRRRPPQ-{βAla}-CWMSPRHLGTC (Disulfide bridge: Cys15-Cys25) |
| Formula | C127H215N53O30S3 |
| Molar Mass | 3060.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Perea S E, et al. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo[J]. Molecular and cellular biochemistry, 2008, 316: 163-167. |
CIGB-300
CAS: 1072877-99-6 F: C127H215N53O30S3 W: 3060.60
CIGB-300 (P15-Tat) is an anti-casein kinase 2 (CK2) peptide that exhibits anticancer properties by interfering with the
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.